Suppressor tRNAs take two translational steps forward

Two new papers offer strategies for how to improve the potency and limit the immunogenicity of suppressor tRNA therapeutics, two of the modality’s persistent challenges.

Suppressor tRNAs are engineered to override a premature stop codon caused by a nonsense mutation, instead inserting an amino acid and allowing translation to continue to produce a full-length protein. Because they recognize a stop codon rather than a particular mutation or gene, they offer a mutation-agnostic approach that could, in principle, treat multiple diseases caused by the same codon...